Back

Need for dosage adjustment during the first year of treatment with non-vitamin k oral anticoagulants in non-valvular atrial fibrillation patients

25 August 2018 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Cardiovascular drug therapy in special populations Anticoagulants ESC Premium Access ESC Congress 2018

About the speaker

Photo
Mr Gines Elvira Ruiz

General University Hospital of Elche, Elche (Spain)

7 More presentations in this session

Presentation thumbnail
Riociguat in transthyretin cardiac amyloidosis-data from a named patient use program in austria
Doctor F. Duca (Vienna, AT)
Abstract
Presentation thumbnail
The monocentric, double-blind, placebo-controlled research of sildenafil impact in pediatric patients with secondary pulmonary hypertension.
Associate Professor I. Palii (Chisinau, MD)
Abstract Slides Video
Presentation thumbnail
Obesity paradox outcomes after acute myocardial infarction in Japanese is due to optimal medical therapy in overweight patients
Assistant Professor K. Sakamoto (Kumamoto, JP)
Abstract Slides Video
Presentation thumbnail
Elucidating the underlying mechanisms for the differential response to sodium channel blocker antiarrhythmic drugs in obese patients with atrial fibrillation
Assistant Professor M. Mccauley (Chicago, US)
Abstract Slides Video
Presentation thumbnail
The impact of additional mineralocorticoid receptor antagonist on guideline-recommended medical therapy in acute heart failure patients with ischemic heart disease.
Doctor T. Abe (Kawagoe, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular drug therapy in special populations

The Event

Event poster

ESC Congress 2018

25 August - 29 August 2018
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources